Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Leuk Lymphoma. 2018 Apr;59(4):983-987. doi: 10.1080/10428194.2017.1361031. Epub 2017 Aug 7.

Affiliation

¹ a Department of Clinical Therapeutics , Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine , Athens , Greece.

PMID: 28782413
DOI: 10.1080/10428194.2017.1361031

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors*
ADP-ribosyl Cyclase 1 / immunology
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Antiprotozoal Agents / therapeutic use
Female
Humans
Immunocompromised Host
Immunosuppression Therapy / adverse effects
Immunosuppression Therapy / methods
Leishmania donovani / isolation & purification
Leishmaniasis, Visceral / drug therapy
Leishmaniasis, Visceral / immunology*
Leishmaniasis, Visceral / parasitology
Male
Membrane Glycoproteins / antagonists & inhibitors*
Membrane Glycoproteins / immunology
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Opportunistic Infections / drug therapy
Opportunistic Infections / immunology*
Opportunistic Infections / parasitology
Recurrence
Signaling Lymphocytic Activation Molecule Family / antagonists & inhibitors*
Signaling Lymphocytic Activation Molecule Family / immunology

Substances

Antiprotozoal Agents
Membrane Glycoproteins
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family
CD38 protein, human
ADP-ribosyl Cyclase 1